Displaying 24 (all) recruiting clinical trials.
-
A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
The purpose of the study is to determine the safety and tolerability of intravenous (IV) administered CLN-049. CLN-049 is a novel BITE therapy that target ... -
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
The primary objectives of this study are to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-75276617, as well as the safety and tolerability ... -
A Phase I First-In-Human Multicenter Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
The purpose of the study is to determine the safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic ... -
A Phase I Open-Label Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended phase 2 dose for FT596 as monotherapy and in combination with rituximab or obinutuzumab for ... -
An Open Label First in Human (FIH) Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda (pembrolizumab) in Advanced or Metastatic Malignancy
The purpose of the study is to look at how your body tolerates LVGN6051, how safe LVGN6051 may be, and how LVGN6051 is taken up ... -
A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
The purpose of the study is to evaluateTRK-950 in combination with 1) FOLFIRI or 2) Gemcitabine / Cisplatin or 3) Gemcitabine / Carboplatin or 4) Ramucirumab/Paclitaxel ... -
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
The purpose of the study is to determine and evaluate the safety, tolerability, and preliminary efficacy of oral LY3537982 as monotherapy and as part of ... -
Phase 1 Open-Label Multicenter Dose Escalation Study of mRNA-2752 a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L IL-23 and IL-36? for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
The purpose of the study is to evaluate the anti-tumor activity of ITu injections of mRNA-2752 alone and in combination with intravenously administered durvalumab in ... -
A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors
If you are diagnosed with stage 4 tumor of any solid origin, for example; breast, endometrial, ovarian, fallopian tube, cervix, vaginal or primary peritoneal cancer ...
-
A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.
You can participate in this study if you are diagnosed with stage 3 or stage 4 skin melanoma. The purpose of this study is to ...